

European Journal of
Immunology
Clinical-Basic-Translational

ECI 2024

DUBLIN 1-4 SEPTEMBER

7th EUROPEAN CONGRESS OF IMMUNOLOGY

Abstract Book

7th EUROPEAN CONGRESS OF IMMUNOLOGY
DUBLIN | IRELAND | 1-4 SEPTEMBER 2024
CONQUERING CHALLENGES WITH IMMUNOLOGY



Irish Society
for Immunology



European Federation of
Immunological Societies

Under the auspices of European Federation
of Immunological Societies,
EFIS and the Irish Society for Immunology

Abstracts

7th European Conference of Immunology

1-4 September, 2024

Dublin, Ireland

This abstract book can be searched using the PDF search function to look, for example, for the Abstract number or author name.

To cite an Abstract, please use the following format:

Abstract title. Authors. Conference: Abstracts. Location Dublin, Ireland. Date September 1-4, 2024. Eur. J. Immunol. 2024.54, S1, page number(s). Meeting Abstract number [the Abstract number can be found above the title]

Table of Contents

ABSTRACT REVIEWERS	9
WORKSHOPS	13
WS01 – ALLERGY AND ASTHMA	14
WS02 – INNATE IMMUNE TRAINING	21
WS03 – IMMUNOMODULATION BY DIET, EXERCISE AND HORMONES	28
WS04 – GRANULOCYTE DIFFERENTIATION AND FUNCTION	35
WS05 – DIVERSITY OF ANTIGEN RECOGNITION	42
WS06 – EPIDEMIOLOGY AND IMMUNOGENETICS	49
WS07 – PARASITE AND BACTERIAL IMMUNOLOGY	56
WS08 – RESPIRATORY IMMUNOLOGY	63
WS09 – NEUROINFLAMMATION I	70
WS10 – BACTERIAL AND VIRAL IMMUNITY	77
WS11 – INNATE AND ADAPTIVE IMMUNE CELLS IN INFLAMMATION	84
WS12 – IMMUNE REGULATION IN DISEASE	91
WS13 – GASTROINTESTINAL IMMUNOLOGY	98
WS14 – TRANSPLANTATION IMMUNOLOGY	105
WS15 – T CELLS IN AUTOIMMUNITY	112
WS16 – B CELLS: DEVELOPMENT AND FUNCTION	119
WS17 – NEUROINFLAMMATION II	126
WS18 – IMMUNE DEFICIENCIES AND IMMUNE DYSFUNCTION	133
WS19 – PATTERN RECOGNITION RECEPTORS AND INNATE IMMUNITY	140

WS20 – MECHANISMS OF ANTIGEN PRESENTATION	147
WS21 – CANCER IMMUNOGENETICS	154
WS22 – CANCER VACCINES AND IMMUNOTHERAPIES	161
WS23 – MACROPHAGE FUNCTION AND REGULATION	168
WS24 – IMMUNOMETABOLISM IN CANCER	175
WS25 – AI AND BIOINFORMATICS	182
WS26 – IMMUNOLOGY OF SKIN DISEASE	189
WS27 – TISSUE MICROENVIRONMENTS-DAMAGE AND REPAIR	196
WS28 – IMMUNE SENESENCE AND AGING	203
WS29 – T CELL IMMUNITY IN CANCER	210
WS30 – NOVEL THERAPEUTICS FOR AUTOIMMUNE DISEASES	217
WS31 – DIET, OBESITY AND IMMUNE MODULATION	224
WS32 – T CELL MEMORY IN HEALTH AND DISEASE	231
WS33 – VACCINES FOR BACTERIAL DISEASES	238
WS34 – IMMUNE IMPAIRMENT AND EXHAUSTION	245
WS35 – TOLERANCE AND IMMUNE REGULATION	252
WS36 – T CELL REGULATION AND FUNCTION I	259
WS37 – B CELLS IN HEALTH AND DISEASE	266
WS38 – IMMUNOMETABOLISM	273
WS39 – NOVEL APPROACHES TO VACCINOLOGY	280
WS40 – BIOINFORMATICS IN IMMUNITY AND DISEASE	287
WS41 – MOLECULAR MECHANISMS IN INNATE IMMUNITY	294
WS42 – NK-BASED CANCER IMMUNOTHERAPIES	301
WS43 – CONTROL OF TISSUE INFLAMMATION AND REPAIR	308

WS44 – COVID-19 IMMUNITY	315
WS45 – STROMAL CELLS IN IMMUNITY AND TISSUE REPAIR	322
WS46 – DENDRITIC CELL DIFFERENTIATION AND FUNCTION	329
WS47 – CAR-T DEVELOPMENT AND DESIGN	336
WS48 – CYTOKINES AND CHEMOKINES IN CANCER	343
WS49 – REGULATION OF ADAPTIVE IMMUNITY	350
WS50 – INNATE IMMUNITY IN CANCER I	357
WS51 – VIRAL IMMUNITY I	364
WS52 – REGULATORY T CELLS IN HOMEOSTASIS AND DISEASE	371
WS53 – T CELLS IN AUTOIMMUNE AND INFLAMMATORY DISEASE	378
WS54 – MICROBIOTA IN HEALTH AND DISEASE	385
WS55 – ADOPTIVE CELL THERAPY FOR CANCER AND INFECTIOUS DISEASE	392
WS56 – REGULATION OF AUTOIMMUNE AND INFLAMMATORY DISEASE	399
WS57 – RESPIRATORY INFLAMMATION	406
WS58 – T CELL REGULATION AND FUNCTION II	413
WS59 – T CELLS IN INFLAMMATORY AND INFECTIOUS DISEASES	420
WS60 – MACROPHAGES IN INFECTIOUS AND AUTOIMMUNE DISEASES	427
WS61 – CANCER IMMUNE REGULATION AND EVASION	434
WS62 – T CELL REGULATION AND FUNCTION III	441
WS63 – GENETIC AND ENVIRONMENTAL TRIGGERS OF AUTOIMMUNITY	448
WS64 – REGULATORY T CELLS: DIFFERENTIATION AND REGULATION	455
WS65 – ADOPTIVE T CELL THERAPY	462
WS66 – CANCER IMMUNE EVASION AND RESISTANCE	469
WS67 – GLYCOSYLATION	476

WS68 – TRANSLATIONAL CANCER IMMUNOLOGY	483
WS69 – CANCER IMMUNOTHERAPIES	490
WS70 – IMMUNITY IN RESPIRATORY INFECTIONS	497
WS71 – VACCINES FOR VIRAL INFECTIONS	504
WS72 – INNATE IMMUNITY IN CANCER II	511
WS73 – VIRAL IMMUNITY II	518
WS74 – TRIGGERS OF AUTOIMMUNE AND INFLAMMATORY DISEASE	525
POSTER SESSION 1	532
P1.01 ADOPTIVE CELL THERAPY	533
P1.02 ALLERGY AND ASTHMA	554
P1.03 ANTIGEN PRESENTATION	590
P1.04 ANTIGENS	602
P1.05 ARTIFICIAL INTELLIGENCE AND IMMUNITY	617
P1.06 B LYMPHOCYTE REGULATION AND FUNCTION	624
P1.07 BACTERIAL, VIRAL, FUNGAL, AND PARASITIC IMMUNOLOGY	651
P1.08 BIOINFORMATICS AND IMMUNOLOGY	709
P1.09 CANCER IMMUNOTHERAPY	730
P1.10 CANCER VACCINES	794
P1.11 CELL COMMUNICATION AND SIGNALING	800
P1.12 CELLULAR MECHANISMS IN INNATE IMMUNOLOGY	813
P1.13 CHEMOKINES AND THEIR RECEPTORS	846
P1.14 CONTROL OF INFLAMMATION AND TISSUE REPAIR	848
P1.15 CYTOKINE AND T LYMPHOCYTE-BASED IMMUNOTHERAPY	928
POSTER SESSION 2	942
P2.01 CYTOKINES AND THEIR RECEPTORS	943

P2.02 DIVERSITY OF ANTIGEN RECOGNITION	953
P2.03 EPITHELIAL AND STROMAL CELLS	955
P2.04 GENETIC AND ENVIRONMENTAL TRIGGERS OF AUTOIMMUNITY	966
P2.05 IMMUNE DEFICIENCIES	1006
P2.06 IMMUNE EXHAUSTION	1042
P2.07 IMMUNE MEMORY DEVELOPMENT	1054
P2.08 IMMUNE REGULATION IN CANCER	1066
P2.09 IMMUNE RESPONSE REGULATION: CELLULAR MECHANISMS	1116
P2.10 IMMUNE RESPONSE REGULATION: MOLECULAR MECHANISMS	1159
P2.11 IMMUNE SENESENCE	1197
P2.12 INNATE LYMPHOID CELLS	1206
P2.14 LYMPHOCYTE DIFFERENTIATION	1215
P2.15 LYMPHOID LINEAGE	1226
P2.16 MAINTENANCE AND LOCAL REGULATION OF TISSUE SPECIFIC IMMUNITY	1230
P2.17 MANIPULATION OF TOLERANCE	1256
P2.18 MECHANISMS OF ATOPIC DISEASE	1266
P2.19 MICROBIOTA	1268
P2.20 MOLECULAR MECHANISMS IN INNATE IMMUNOLOGY	1284
P2.21 MUCOSAL IMMUNITY	1309
P2.22 MYELOID LINEAGE	1345
POSTER SESSION 3	1357
P3.01 NEUROINFLAMMATION	1358
P3.02 NOVEL APPROACHES TO VACCINOLOGY	1418
P3.03 PATTERN RECOGNITION RECEPTORS	1434

P3.04 POLYMORPHISMS AND MUTATIONS IN IMMUNOGENETICS	1440
P3.05 T LYMPHOCYTE REGULATION AND FUNCTION	1449
P3.06 THERAPY IN AUTOIMMUNITY	1514
P3.07 THERAPY OF ALLERGY AND HYPERSENSITIVITY	1547
P3.08 TRANSPLANTATION IMMUNOLOGY	1551
P3.09 TUMOR MICROENVIRONMENT	1583
P3.10 VACCINES	1631
P3.11 VACCINES FOR IMMUNOTHERAPY	1668
P3.12 VIRAL IMMUNOLOGY	1676
P3.13 VISUALIZING IMMUNE RESPONSE	1732

ABSTRACT REVIEWERS

The organizers of the 7th European Congress of Immunology would like to extend their special thanks to all abstract reviewers for their contribution and time dedicated to the success of the congress:

Mariastefania Antica	Croatia
Silke Appel	Norway
Arzu L. Aral	Turkey
Michelle E. Armstrong	Ireland
Attila Bácsi	Hungary
Péter Balogh	Hungary
Zsuzsanna Barad	Ireland
Laurence Bataille	France
Rami Bechara	France
Kamel Benlagha	France
Michael Berger	Israel
Stefania Bjarnarson	Iceland
Jeroen Bogie	Belgium
Mariana Borsa	United Kingdom
Daniela Bosisio	Italy
Kiva Brennan	Ireland
Elizabeth Brint	Ireland
Kelly Bruton	USA
Milan Buc	Slovakia
Biljana Bufan	Serbia
Alice Burton	United Kingdom
Krisztina Buzás	Hungary
Ricardo Calderón González	United Kingdom
Iris Caramalho	Portugal
Ignazio Caruana	Germany
Féaron Cassidy	Ireland
Roberta Castriconi	Italy
Amanpreet Singh Chawla	United Kingdom
Mathieu Chevalier	France
Ceren Çiracı	Turkey
Mark Coles	United Kingdom
Rebecca Coll	Ireland
Odilia Corneth	Netherlands
Indrė Dalgėdienė	Lithuania
Esther de Jong	Netherlands
Oscar De la Calle – Martin	Spain
Diletta Di Mitri	Italy
Laure Dumoutier	Belgium
Wilfried Ellmeier	Austria
Karen English	Ireland

Güneş Esendağlı	Turkey
Marion Espéli	France
Christine Falk	Germany
Cristhiane Favero de Aguiar	Ireland
Marta Ferreira-Gomes	Germany
Iva Filipovic	Sweden
Dominik Filipp	Czech Republic
Reinhold Förster	Germany
Asimina Fylaktou	Greece
Felipe Galvez-Cancino	United Kingdom
Ro'i Gazit	Israel
Deena Gibbons	United Kingdom
Katharina Glosse	Germany
Iria Gomez Tourino	Spain
Stephen Gordon	Ireland
Danka Grčević	Croatia
Ola Grimsholm	Austria
Bilgi Güngör	Turkey
Pramod Gupta	India
Iva Hafner Bratkovič	Slovenia
Linda Hammerich	Germany
Megan Hanlon	Ireland
Rune Hartmann	Denmark
Annika Hausmann	Denmark
Heike Hawerkamp	Ireland
Peter Heeringa	Netherlands
Niels Hellings	Belgium
Karin Hoffmann-Sommergruber	Austria
Marion Humbert	Sweden
Fiachra Humphries	USA
Hind Hussein	Belgium
Hanna Jarva	Finland
Chandima Jeewandara	Sri Lanka
Emmanuelle Jouanguy	France
Nemanja Jovičić	Serbia
Nidhi Kedia-Mehta	Ireland
Kai Kisand	Estonia
Sylvia Knapp	Austria
Natalja Kurjane	Latvia
Mila Kverka	Czech Republic
Federica Laudisi	Italy
Ed Lavelle	Ireland
Emma Leacy	Ireland
Vladimir Leksa	Slovakia
Andri Lemarquis	USA
Francesco Liotta	Italy
Stephanie Longet	France

Joanne Lysaght	Ireland
Jenny Mannion	USA
Emiliano Marasco	Italy
Vera Martins	Portugal
Viviana Marzaioli	Ireland
Craig McEntee	Ireland
Eóin McNamee	Ireland
Agata Mlynska	Lithuania
Attila Mócsai	Hungary
Slavko Mojsilović	Serbia
Gustavo Monasterio	Sweden
Brenda Morris	Ireland
Myriam Nabhan	Ireland
Pascal Naef	USA
Samuel Nobs	Israel
Maxim Nosenko	Ireland
Megan O'Brien	Ireland
Cliona O'Farrelly	Ireland
Ewa Oleszycka	Poland
Luke O'Neill	Ireland
Barbaros Oral	Turkey
Didem Ozkazanc	Turkey
Vered Padler-Karavani	Israel
Laura Pallett	United Kingdom
Efimia Papadopoulou-Alataki	Greece
Joaquin Pellegrini	France
Anne M Pesenacker	United Kingdom
Pärt Peterson	Estonia
Andreea Petrasca	Ireland
Eva Piano-Mortari	Italy
Silvia Piconese	Italy
Bojan Polić	Croatia
Wilfried Posch	Austria
Hannah Prendeville	Ireland
Otoniel Rodríguez Jorge	Mexico
Nicolas Ruffin	Sweden
Marah Runtsch	Austria
Aideen Ryan	Ireland
Sinéad Ryan	Ireland
Manolo Sambucci	Italy
Silvia Sanchez-Ramon	Spain
Ioana Sandu	Sweden
Güher Saruhan-Direskeneli	Turkey
Ayça Sayi Yazgan	Turkey
Hansjörg Schild	Germany
Martin Schwarzer	Czech Republic
Anna Sediva	Czech Republic

Martynas Simanavičius	Lithuania
Milada Sirova	Czech Republic
Linda Slot	Netherlands
Hermelijn Smits	Netherlands
Matthaios Speletas	Greece
Ilja Striz	Czech Republic
Johanna Strobl	Austria
Alan Šućur	Croatia
Jamie Sugrue	France
Tolga Sutlu	Turkey
Eva Sverremark Ekstrom	Sweden
Katerina Tarassi	Greece
Eleonora Timperi	Italy
Christina Tsigalou	Greece
Ubaid Ullah Kalim	Finland
Wendy Unger	Netherlands
Luca Vannucci	Czech Republic
Angeliki Vittoraki	Greece
Carsten Watzl	Germany
Jurgen Wittmann	Germany
Christine Wuebben	Germany
Elena Zenaro	Italy
Jacques Zimmer	Luxembourg

403 – P3.02.04

Inorganic fullerene-like tungsten disulfide nanoparticles strongly modulate the immune response in vitro

Darinka Popović¹, Snežana Zečević¹, Sergej Tomić², Marina Bekić², Sara Rakočević¹, Maja Kosanović², Dušica Stojanović³, Petar Uskoković³, Milan Marković², Dejan Bokonjić¹, Miodrag Čolić^{1,4}

¹Medical Faculty Foca, University of East Sarajevo, Foča, Bosnia and Herzegovina; ²Institute for the Application of Nuclear Energy, University of Belgrade, Belgrade, Serbia; ³Faculty of Technology and Metallurgy, University of Belgrade, Belgrade, Serbia; ⁴Serbian Academy of Sciences and Arts, Belgrade, Serbia

Purpose: Tungsten disulfide (WS₂) nanoparticles have been extensively investigated in the biomedical field as theranostics due to their specific properties, including good biocompatibility. However, almost nothing is known about their effect on the immune system. This study aimed to investigate the effects of inorganic fullerene-like WS₂ (IF-WS₂) nanostructures on the immune response in vitro.

Methods: IF-WS₂ nanoparticles, were used in three in vitro culture models: peripheral blood mononuclear cells (PBMCs) stimulated with phytohemagglutinin (PHA); monocyte-derived dendritic cells (MoDCs) co-cultivated with purified T cells; monocyte-derived macrophages (MoMs) and U937 cell line cultivated under M1 or M2 polarizing conditions. Several parameters were analyzed: cytotoxicity; internalization of nanoparticles by immune cells (morphological and flow cytometric analysis); T-cell proliferation of CellTrace Far Red prestained cells; production of cytokines and chemokines in culture supernatants and intracellularly; analysis of cell markers in/on MoDCs, MoMs, and T cells.

Results: IF-WS₂ were non-cytotoxic up to the concentration of 200 µg/mL. However, the concentrations of 25 µg/mL and higher inhibited PHA-stimulated proliferation of PBMC, T cells in co-culture with IF-WS₂-treated MoDCs, but not purified T cells stimulated with CD3/CD28 beads. Morphological and flow cytometric data showed a dose- and time-dependent internalization of IF-WS₂ by MoMs and MoDCs but not lymphocytes. IF-WS₂ decreased the production of pro-inflammatory cytokines/chemokines (IL-1β, TNF-α, IL-8, MCP-1, and GRO-α) by PHA-stimulated PBMC. The Th1 (IFN-γ), Th17 (IL-17A, IL-17F, and IL-22), and Th21 (IL-21) cytokines were down-regulated, whereas Th2 (IL-4, IL-5, and IL-3), Th9 (IL-9) cytokines and a T regulatory cytokine (IL-10) were up-regulated. These effects were also seen in IF-WS₂-MoDC/T-cell cocultures and were correlated with inhibited differentiation, and maturation of MoDCs as well as the induction of their tolerogenic properties as judged by increased expression of tolerogenic markers (ILT4 and IDO-1), decreased production of IL-12 and the increased potency to induce differentiation of Tregs. In addition, IF-WS₂ nanoparticles were capable of decreasing M1 and increasing M2 polarizing properties of both MoMs and U937 cells.

Conclusion: IF-WS₂ nanoparticles exert a very potent modulation of the immune response in vitro through their action on antigen-presenting cells.